Figure 8.
Neutralizing monoclonal anti-TGF-β1 (4A11) counteracts the protective effect of latent TGF-β1-transduced MBP-specific T cells. Mice were induced to develop EAE as in Fig. 4. Two groups of mice received 3 × 106 antigen-activated, latent TGF-β1-transduced, MBP-specific T cells on day 13 after immunization with PLP + CFA. One of these groups also received 0.5 mg anti-TGF-β1, 4A11, i.p. on day 13 (n = 6, ▴). This group initially developed EAE similar to the control group with or without anti-TGF-β1 (n = 11; •), significantly more severe (P < 0.05, day 17, and < 0.01, days 18 and 19) than in the group receiving cells alone (n = 5, ■). ∗, P < 0.05; ∗∗, P < 0.01.